Absci to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) announced its participation in the Stifel Healthcare Conference in New York on November 16, 2022, at 4:10 p.m. ET. The company, known for leveraging generative AI and biological data in therapeutic design, will host a fireside chat, accessible via their investor relations website. Absci focuses on drug discovery and the development of protein-based therapeutics using its Integrated Drug Creation™ platform, aiming to enhance the creation of innovative drugs such as Bionic™ proteins.

VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the company will be participating in the upcoming Stifel Healthcare Conference in New York, NY.

Absci management is scheduled to participate in a fireside chat on Wednesday, November 16^th at 4:10 p.m. Eastern Time (1:10 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com 

Media Contact
press@absci.com 

FAQ

What is the date and time of Absci's fireside chat at the Stifel Healthcare Conference?

Absci's fireside chat is scheduled for November 16, 2022, at 4:10 p.m. ET.

Where can I access the webcast for Absci's presentation?

The webcast can be accessed on Absci's investor relations website at investors.absci.com.

What is the focus of Absci Corporation's technology?

Absci focuses on drug and target discovery using deep learning AI and synthetic biology to develop protein-based therapeutics.

What unique products does Absci aim to create?

Absci aims to create next-generation protein-based drugs, including Bionic™ proteins with nonstandard amino acids.

How does Absci plan to improve drug development?

Absci plans to enhance drug development by identifying novel drug targets and streamlining the discovery of biotherapeutic candidates through its Integrated Drug Creation™ platform.